Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure

Donna M. Mancini, Stuart D. Katz, Chim C. Lang, John LaManca, Alhakam Hudaihed, Ana-Silvia Androne

    Research output: Contribution to journalArticle

    452 Citations (Scopus)

    Abstract

    Background— Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF. Methods and Results— Twenty-six anemic patients aged 57±11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [O2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of O2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P<0.05). There were significant increases in hemoglobin (11.0±0.5 to 14.3±1.0 g/dL, P<0.05), peak O2 (11.0±1.8 to 12.7±2.8 mL · min-1 · kg-1, P<0.05) and exercise duration (590±107 to 657±119 s, P<0.004) in the EPO group but no significant changes in the control group. Resting and hyperemic forearm vascular resistance and indices of the rate of muscle oxidative capacity were unchanged in both groups. Conclusion— EPO significantly enhances exercise capacity in patients with CHF. One mechanism of improvement in O2 is increased oxygen delivery from increased hemoglobin concentration.
    Original languageEnglish
    Pages (from-to)294-299
    Number of pages6
    JournalCirculation
    Volume107
    Issue number2
    DOIs
    Publication statusPublished - Jan 2003

    Fingerprint

    Erythropoietin
    Heart Failure
    Exercise
    Hemoglobins
    Forearm
    Placebos
    Oxygen
    Muscles
    Plasma Volume
    Hematocrit
    Oxygen Consumption
    Vascular Resistance
    Control Groups

    Keywords

    • Exercise
    • Heart failure
    • Growth substances
    • Erythropoietin
    • Therapeutic use

    Cite this

    Mancini, Donna M. ; Katz, Stuart D. ; Lang, Chim C. ; LaManca, John ; Hudaihed, Alhakam ; Androne, Ana-Silvia. / Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. In: Circulation. 2003 ; Vol. 107, No. 2. pp. 294-299.
    @article{9ff02e03b7634ce69cd5a31e3eb80681,
    title = "Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure",
    abstract = "Background— Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF. Methods and Results— Twenty-six anemic patients aged 57±11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [O2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of O2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P<0.05). There were significant increases in hemoglobin (11.0±0.5 to 14.3±1.0 g/dL, P<0.05), peak O2 (11.0±1.8 to 12.7±2.8 mL · min-1 · kg-1, P<0.05) and exercise duration (590±107 to 657±119 s, P<0.004) in the EPO group but no significant changes in the control group. Resting and hyperemic forearm vascular resistance and indices of the rate of muscle oxidative capacity were unchanged in both groups. Conclusion— EPO significantly enhances exercise capacity in patients with CHF. One mechanism of improvement in O2 is increased oxygen delivery from increased hemoglobin concentration.",
    keywords = "Exercise, Heart failure, Growth substances, Erythropoietin, Therapeutic use",
    author = "Mancini, {Donna M.} and Katz, {Stuart D.} and Lang, {Chim C.} and John LaManca and Alhakam Hudaihed and Ana-Silvia Androne",
    note = "dc.publisher: American Heart Association dc.description.sponsorship: Division of Research Resources, General Clinical Research Centers Program, NIH 5 MO1 RR00645",
    year = "2003",
    month = "1",
    doi = "10.1161/01.CIR.0000044914.42696.6A",
    language = "English",
    volume = "107",
    pages = "294--299",
    journal = "Circulation",
    issn = "0009-7322",
    publisher = "American Heart Association",
    number = "2",

    }

    Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. / Mancini, Donna M.; Katz, Stuart D.; Lang, Chim C.; LaManca, John; Hudaihed, Alhakam; Androne, Ana-Silvia.

    In: Circulation, Vol. 107, No. 2, 01.2003, p. 294-299.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure

    AU - Mancini, Donna M.

    AU - Katz, Stuart D.

    AU - Lang, Chim C.

    AU - LaManca, John

    AU - Hudaihed, Alhakam

    AU - Androne, Ana-Silvia

    N1 - dc.publisher: American Heart Association dc.description.sponsorship: Division of Research Resources, General Clinical Research Centers Program, NIH 5 MO1 RR00645

    PY - 2003/1

    Y1 - 2003/1

    N2 - Background— Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF. Methods and Results— Twenty-six anemic patients aged 57±11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [O2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of O2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P<0.05). There were significant increases in hemoglobin (11.0±0.5 to 14.3±1.0 g/dL, P<0.05), peak O2 (11.0±1.8 to 12.7±2.8 mL · min-1 · kg-1, P<0.05) and exercise duration (590±107 to 657±119 s, P<0.004) in the EPO group but no significant changes in the control group. Resting and hyperemic forearm vascular resistance and indices of the rate of muscle oxidative capacity were unchanged in both groups. Conclusion— EPO significantly enhances exercise capacity in patients with CHF. One mechanism of improvement in O2 is increased oxygen delivery from increased hemoglobin concentration.

    AB - Background— Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF. Methods and Results— Twenty-six anemic patients aged 57±11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [O2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of O2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P<0.05). There were significant increases in hemoglobin (11.0±0.5 to 14.3±1.0 g/dL, P<0.05), peak O2 (11.0±1.8 to 12.7±2.8 mL · min-1 · kg-1, P<0.05) and exercise duration (590±107 to 657±119 s, P<0.004) in the EPO group but no significant changes in the control group. Resting and hyperemic forearm vascular resistance and indices of the rate of muscle oxidative capacity were unchanged in both groups. Conclusion— EPO significantly enhances exercise capacity in patients with CHF. One mechanism of improvement in O2 is increased oxygen delivery from increased hemoglobin concentration.

    KW - Exercise

    KW - Heart failure

    KW - Growth substances

    KW - Erythropoietin

    KW - Therapeutic use

    U2 - 10.1161/01.CIR.0000044914.42696.6A

    DO - 10.1161/01.CIR.0000044914.42696.6A

    M3 - Article

    VL - 107

    SP - 294

    EP - 299

    JO - Circulation

    JF - Circulation

    SN - 0009-7322

    IS - 2

    ER -